Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma
Pfizer (NYSE: PFE), a leading pharmaceutical company in the US, has announced that it has...
Cancer
Allist Pharmaceuticals Secures NMPA Approval for Phase I Study of AST2169 Liposome in KRAS G12D Tumors
Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) has received clearance from the National Medical...
Genor Biopharma Secures NMPA Review for Lerociclib in Advanced Breast Cancer Indication
Genor Biopharma Co., Ltd. (HKG: 6998) has announced that the National Medical Products Administration (NMPA)...
Pfizer’s Adcetris Combo Shows Improved Survival in Relapsed/Refractory DLBCL Late-Stage Trial
Pfizer (NYSE: PFE) has announced positive results from a late-stage clinical trial for its antibody-drug...
MSD Strikes Deal with Pearl Bio to Tap into Synthetic Biology for Oncology Targets
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a strategic agreement with Pearl...
MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ:...
Bio-Thera Solutions Gets Green Light for Phase Ib/II Study of ADC BAT8008 in Advanced Solid Tumors
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that it has received approval from the National...
Betta Pharmaceuticals’ Ensartinib Accepted for FDA Review for First-Line ALK+ NSCLC Treatment
Betta Pharmaceuticals (SHE: 300558), a pharmaceutical company based in China, has announced that the market...
InnoCare Pharma Receives IND Approval in China for BCL2 Inhibitor Combo Therapy
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has announced that it has...
Simcere Pharmaceutical Gets NMPA Approval for Clinical Study of Trispecific Antibody SIM0500
Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that it...
Kexing Pharmaceutical Secures Rights for Chia Tai Tianqing’s Generic Ibrance in 11 Countries
Kexing Pharmaceutical (SHA: 688136), based in China, has entered into an international collaboration agreement with...
Kelun-Biotech’s A400 Receives Fast-Track Status from FDA for RET Fusion-Positive NSCLC
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that its innovative drug development subsidiary, Sichuan...
Sinocelltech Gains NMPA Approval for Clinical Study of SCTB35 in B-Cell Non-Hodgkin’s Lymphoma
Sinocelltech Group Ltd (SHA: 688520), based in China, has announced that it has received clearance...
Innovent and HutchMed’s Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer
China’s Center for Drug Evaluation (CDE) has indicated that the combination therapy of Innovent Biologics...
Simcere Secures FDA Approval for Clinical Study of Trispecific Antibody SIM0500 in Multiple Myeloma
Simcere Pharmaceutical Group (HKG: 2096), based in China, has received approval from the U.S. Food...
Lepu Biotechnology’s MRG004A ADC Gains Fast Track Designation for Pancreatic Cancer
Lepu Biotechnology Co., Ltd. (HKG: 2157), based in China, has announced that its in-house developed...
Merck’s 2023 Annual Report: A Mixed Bag Amid Global Challenges
Merck KGaA (ETR: MRK), a leading German chemical, reported a 5.6% decline in its global...
BMS’s Opdivo Secures FDA Approval for First-Line Urothelial Carcinoma Treatment
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...
Shanghai Fosun Pharma Gets NMPA Green Light for Universal NK Cell Therapy GCK-01 Clinical Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
Shanghai Fosun Pharma Gets NMPA Green Light for XS-02 Solid Tumor Clinical Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...